Trial Profile
A Randomized, Double-blind, Placebo Controlled Study to Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 (Sequential Administration of a Fixed Dose of VAK694 and Single Ascending Doses of QAX576) in Patients With Well-controlled Mild to Moderate Asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2020
Price :
$35
*
At a glance
- Drugs Dectrekumab (Primary) ; VAK 694 (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- 13 Apr 2012 New trial record